MRNA
Moderna Inc
$145.55-2.23%
Setup
Watch
Buy Zone
$148.67-$156.1
Sector
Biotechnology
Industry
Biotechnology
40
Recommendation
Extended
Avoid
Setup may be valid but price is no longer in a clean buy zone.
MRNA chart
Loading chart…
ADX
Developing34.9Long Term
Up ↑Intermediate Term
Up ↑Short Term
Up ↑Overall Quality40
RS Rating
99
relative strength
Fundamentals
33
Weak fund-Q
Volume Demand
45
-3% vs avg
Technical Setup
50
4/8 checks
Industry/Theme
91
Biotechnology
Trade Plan
Extended
Entry
$148.67
Entry Zone
$148.67-$156.1
Stop / Risk
$136.78
RS Rating
99
Volume confirmed
No
Targets
$178.4 / $185.84
Breakout · IBD Setup
4 ✓ 4 ✗
Entry $148.67–$156.1Stop $136.78Target $178.4 / $185.84
Market regimeUptrend
Quality40
RS Rating99
Above 50-MA+70.24%
Above 200-MA+165.49%
VolumeWeak
In Buy ZoneNo
Not extendedExtended
Invalidation · Close below stop
How this came together
40
MarketUptrend
SetupWatch
ConfidenceExperimental · not backtested
Fund-Q33 · Weak
StatusAvoid
Stock Data
52-Week Range22 – 177
Price % Chg YTD393.56%
Price % Chg 4wk170.24%
50-Day Avg Vol15.5 Mil
P/E Ratio—
Market Cap$58B
SectorHealthcare
IndustryBiotechnology
Company Fundamentals
EPS % Chg (Qtr)7.6%
Sales % Chg (Qtr)2.11%
EPS Growth 5y-29.93%
Sales Growth 5y19.33%
Annual ROE-39%
Gross Margin12.57%
Operating Margin-149.01%
Net Margin-141.43%
Debt / Equity0.19
Setup levels
Current price
$145.55
Pivot
$148.67
Distance to buy
-17.6%
52-week range
22.28-176.66
Trigger evidence
No active trigger evidence available.
Financial health checks
3/5
Return on equity above 15%
ROE -39%
Net margin above 10%
Net margin -141.43%
EPS growing quarter on quarter
EPS q/q 7.6%
Sales growing quarter on quarter
Sales q/q 2.11%
Debt to equity below 1.0
D/E 0.19
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE-39%
vs sector -61.1%
Net margin-141.43%
vs sector -158.5%
Gross margin12.57%
vs sector -54.1%
EPS growth q/q7.6%
vs sector -0.4%
Sales growth q/q2.11%
vs sector -16.4%
Debt / equity0.19
vs sector -0.45
Business quality
33
GradeWeak
EPS rating23
P/E—
Market cap$58B
IndustryBiotechnology
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Fail
Nicht überextended
Fail
Über 21-EMA
Pass
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-09-03
Trigger date
—
Days on list
4
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.